A Phase 3 interventional study of Alisertib and Pralatrexate in Relapsed Peripheral T-Cell Lymphoma and Refractory Peripheral T-Cell Lymphoma, sponsored by Millennium Pharmaceuticals, Inc.. Completed at 152 sites in 31 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-07-31.
Sponsored by Millennium Pharmaceuticals, Inc. (part of Takeda) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 164 studies in Lymphoma, T-Cell, Peripheral with a site in United States — 21 open to participants now, 28 under way, 2 of them phase 3. Lymphoma, T-Cell, Peripheral · United States.
Among the 164 studies in Lymphoma, T-Cell, Peripheral with a site in United States, this one is the 4th largest by enrollment of the 157 interventional ones that give a count, is one of 9 that started in 2012, is one of 5 in phase 3, and was the 65th registered.
372 studies on the registry are indexed under Lymphoma, T-Cell, Peripheral; 110 are open to participants now.
Browse Lymphoma, T-Cell, Peripheral studies →21 of the 164 studies in Lymphoma, T-Cell, Peripheral with a site in United States are open now. Recruiting first, the newest first:
Kyowa Kirin, Inc. · Sites in United States, Italy, Spain
Ages 18+
Natera, Inc. · Sites in United States
Ages 18+
National Cancer Institute (NCI) · Sites in United States
Ages 18–120
Ohio State University Comprehensive Cancer Center · Sites in United States
Ages 18+
Incyte Corporation · Sites in United States, Australia, Belgium and 2 more countries
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 76 Lymphoma, T-Cell, Peripheral studies recruiting now, 30 (39%) set no upper age limit and 38 (50%) stop at 75 or younger; 5 take children under 18; none take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
164 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 89 · Phase 2 78 · Phase 3 5
First in 1988; this study’s year is marked. 9 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 271 is above the median of 44 across 328 interventional studies indexed under Lymphoma, T-Cell, Peripheral.
Median enrollment 36 across the 157 interventional studies, 800 across the 7 observational. Of the 126 that completed or were terminated, 72 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
64 of 164 have an industry lead sponsor. The 10 most frequent:
This study is registered under Millennium Pharmaceuticals, Inc., one of the names counted as Takeda. Under that name alone:
Millennium Pharmaceuticals, Inc. is the lead sponsor of 178 studies on the registry; none are open to participants now.
Of its 74 completed or terminated interventional studies of FDA-regulated products, 73 (99%) have results posted.
Takeda has 3 studies filed under Lymphoma, T-Cell, Peripheral — fewer than ten, so there is no comparison to draw.
9 of the studies in Lymphoma, T-Cell, Peripheral with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06561048Phase 3Corvus Pharmaceuticals, Inc.Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma | 2027-11 |
| NCT06131801Children's Hospital Medical Center, CincinnatiPharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution | 2026-12-01 |
| NCT03964480Associazione Angela Serra per la ricerca sul cancroProspective Observational International Registry of Patients With Newly Diagnosed Peripheral T Cell Lymphoma. | 2026-12-30 |
| NCT07388563National Cancer Institute (NCI)Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma | 2027-03-31 |
| NCT04068597CellCentric Ltd.Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies | 2027-03-31 |
Add all 9 to your calendar (.ics) → With an account.
Among the 164 studies in Lymphoma, T-Cell, Peripheral with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a phase 3, randomized, 2-arm, open-label, international trial evaluating alisertib compared with single-agent treatment, as selected by the investigator from the offered options of pralatrexate or gemcitabine or romidepsin, in participants with relapsed or refractory peripheral T-cell lymphoma (PTCL). Note: romidepsin was not used as a single-agent comparator outside the United States of America (USA) as supply was not available.
The drug being tested in this study was Alisertib. Alisertib was tested to treat people who have relapsed/refractory peripheral T-cell lymphoma (PTCL).
This study evaluated alisertib for the improvement in overall response rate (ORR) compared with single-agent treatment, as selected by the investigator from the offered options of pralatrexate, romidepsin (US only), or gemcitabine, in participants with relapsed or refractory PTCL.
The study enrolled 271 patients. Participants were randomized (1:1) to one of 2 treatment arms:
This multi-center trial was conducted worldwide. The overall time to participate in this study was approximately 5 years. Participants made multiple visits to the clinic, and then were contacted by telephone up to 42-months after the last participant was randomized, or until death, for follow-up assessment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Alisertib 50 mg, enteric-coated tablet formulation, orally, twice daily for 7 consecutive days (Cycle Days 1-7) in a 21-day cycle (Up to 148 Weeks).
Drug: Alisertib
Pralatrexate 30 mg/m\^2, intravenous (IV) push over 3 to 5 minutes, once weekly, for 6 weeks in 7-week cycles with concurrent vitamin B12 and folic acid supplementation. Cycles were repeated every 7-weeks provided the participant continued to benefit from and tolerate the therapy (Up to 115 Weeks), or Gemcitabine 1,000 mg/m\^2 over 30 minutes, intravenously, on Days 1, 8, and 15 of a 28-day cycle until the absence of disease progression or unacceptable toxicity (Up to 32 Weeks), or Romidepsin 14 mg/m\^2, intravenously over a 4-hour period, on Days 1, 8, and 15 of a 28-cycle. Cycles were repeated every 28 days provided the patient continued to benefit from and tolerate the therapy (Up to 30 Weeks).
Drug: Pralatrexate · Drug: Gemcitabine · Drug: Romidepsin
Alisertib enteric coated tablets
Pralatrexate IV infusion
Gemcitabine IV infusion
Romidepsin IV infusion
Overall Response Rate (ORR) Based on Independent Review Committee (IRC) Assessment
ORR was defined as the percentage of participants who achieve Complete Response (CR) or Partial Response (PR) as assessed by the IRC using International Working Group (IWG) criteria. CR=Disappearance of all evidence of disease and PR=Regression of measurable disease and no new sites.
Time frame: Every 8 weeks from date of first dose treatment; every 12 weeks after 40 week assessment; at end of treatment visit until progressive disease. Duration is approximately 3 years
Progression-Free Survival (PFS) Based on IRC Assessment
PFS was defined as the time from the date of randomization to the date of first documentation of progressive disease (PD) or death due to any cause, whichever occurred first.
Time frame: Every 8 weeks from date of first dose treatment; every 12 weeks after 40 week assessment; at end of treatment visit until progressive disease. Duration is approximately 3 years
Overall Survival (OS)
OS was defined as the time from the date of randomization to the date of death. Participants without documentation of death were censored at the date last known to be alive.
Time frame: Participants were followed for survival for 2 years from date of last participant off study treatment, or death, whichever occurs first. Contacts were every 4 months (Median follow-up 519 days in the alisertib arm and 586 days in the comparative arm)
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A TEAE is defined as an adverse event with an onset that occurs after receiving study drug. A SAE is any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or prolongation of an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly/ birth defect or is a medically important event.
Time frame: First dose to 30 days after last dose of study drug or comparator (Up to 152 Weeks)
Number of Participants With Clinically Important Abnormal Laboratory Values Reported as AEs
Clinical laboratory tests included chemistry, hematology and urinalysis test. Clinically significant treatment-emergent laboratory abnormalities were reported by the investigator as TEAEs.
Time frame: First dose to 30 days after last dose of study drug or comparator (Up to 152 Weeks)
Number of Participants With Clinically Important Vital Sign Measurements Reported as AEs
Vital signs included blood pressure, heart rate and temperature. Individual clinically significant changes in vital signs were reported by the investigator as TEAEs.
Time frame: First dose to 30 days after last dose of study drug or comparator (Up to 152 Weeks)
Complete Response (CR) Rate
Complete Response (CR) rate is defined as the percentage of participants with CR as assessed by the IRC using IWG criteria (2007 Cheson). CR= Disappearance of all evidence of disease.
Time frame: At the end of every 8 weeks from date of first dose treatment; every 12 weeks after 40 week assessment; at end of treatment visit until PD (approximately 3 years)
Time to Disease Progression (TTP)
Time to Progression (TTP) was defined as the time from the date of randomization to the date of first documentation of PD/relapse.
Time frame: At the end of every 8 weeks from date of first dose treatment; every 12 weeks after 40 week assessment; at end of treatment visit until progressive disease. Duration is approximately 3 years
Duration of Response (DOR)
DOR was defined as the time from the date of first documentation of a PR or better to the date of first documentation of progressive disease (PD)/relapse for responders as assessed by the IRC using IWG criteria. Responders without documentation of PD/relapse were censored at the date of last response assessment that was stable disease (SD) or better.
Time frame: At the end of every 8 weeks from date of first dose treatment; every 12 weeks after 40 week assessment; at end of treatment visit until progressive disease. Duration is approximately 3 years
Time to Response
Time to Response is defined as the time from the date of randomization to the date of first documentation of PR or better.
Time frame: At the end of every 8 weeks from date of first dose treatment; every 12 weeks after 40 week assessment; at end of treatment visit until progressive disease. Duration is approximately 3 years
Time to Subsequent Antineoplastic Therapy
Time to subsequent antineoplastic therapy was defined as the time from randomization to the first date of subsequent antineoplastic therapy (excluding transplant). Participants without subsequent antineoplastic therapy were censored at the date of death or last known to be alive.
Time frame: From date of last study drug to date of subsequent antineoplastic therapy, if required; approximately 3 years
Plasma Concentration-time Data to Contribute to Future Population Pharmacokinetics (PK) Analysis
Time frame: Cycle 1, Days 1 and 7; Cycle 2, Day 8; Cycle 3, Day 8; Cycle 4, Day 8. Duration is approximately 4 months.
Change Form Baseline in Reported Symptoms and Quality of Life (QoL) Assessment Per Functional Assessment of Cancer Therapy-Lymphoma (FACT-LYM) for Functioning and Symptoms
The FACT-LYM includes the Functional Assessment of Cancer Therapy General Scale (FACT-G) and a 15-item lymphoma-specific subscale (LYM) over the past week. The FACT-G has 27 items that incorporate 4 scales including physical well-being (PWB; 7 items), social/family well-being (SWB, 7 items), emotional well-being (EWB; 6 items), and functional well-being (FWB; 7 items). The combined FACT-LYM instrument consists of a total of a 42 item questionnaire. Each question is answered on a 5- point scale of 0 (not at all) to 4 (very much) for a total possible score of 168. Higher scores indicate better well-being and a positive change from Baseline indicates improvement.
Time frame: Baseline and End of Treatment (EOT) (Up to 152 Weeks)
Participants took part in the study at 105 investigative sites in the United States including Puerto Rico, Canada, European Union, Russian Federation, Turkey, Israel, Australia, New Zealand and Latin America from 11 June 2012 to the end of study on 18 December 2017.
| Milestone | Alisertib | Pralatrexate, or Romidepsin, or Gemcitabine |
|---|---|---|
| Started | 138 | 133 |
| Safety population: received study drug | 137 | 127 |
| Completed | 0 | 0 |
| Not completed | 138 | 133 |
| Withdrew: Progressive disease | 65 | 53 |
| Withdrew: Unsatisfactory therapeutic response | 37 | 23 |
| Withdrew: Adverse event | 18 | 22 |
| Withdrew: Withdrawal by participant | 8 | 13 |
| Withdrew: Hematopoietic stem cell transplant | 3 | 9 |
| Withdrew: Other reason | 1 | 5 |
| Withdrew: Study terminated by sponsor | 5 | 2 |
| Withdrew: Did not receive study drug | 1 | 6 |
ORR was defined as the percentage of participants who achieve Complete Response (CR) or Partial Response (PR) as assessed by the IRC using International Working Group (IWG) criteria. CR=Disappearance of all evidence of disease and PR=Regression of measurable disease and no new sites.
| percentage of participants | Alisertib | Pralatrexate, or Romidepsin, or Gemcitabine |
|---|---|---|
| Overall Response Rate (ORR) Based on Independent Review Committee (IRC) Assessment | 33 (24 to 43) | 45 (34 to 55) |
PFS was defined as the time from the date of randomization to the date of first documentation of progressive disease (PD) or death due to any cause, whichever occurred first.
| days | Alisertib | Pralatrexate, or Romidepsin, or Gemcitabine |
|---|---|---|
| Progression-Free Survival (PFS) Based on IRC Assessment | 115 (83 to 174) | 104 (61 to 114) |
OS was defined as the time from the date of randomization to the date of death. Participants without documentation of death were censored at the date last known to be alive.
| days | Alisertib | Pralatrexate, or Romidepsin, or Gemcitabine |
|---|---|---|
| Overall Survival (OS) | 415 (263 to 514) | 367 (258 to 572) |
An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A TEAE is defined as an adverse event with an onset that occurs after receiving study drug. A SAE is any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or prolongation of an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly/ birth defect or is a medically important event.
| participants | Alisertib | Pralatrexate, or Romidepsin, or Gemcitabine |
|---|---|---|
| TEAE | 136 | 126 |
| SAE | 75 | 69 |
Clinical laboratory tests included chemistry, hematology and urinalysis test. Clinically significant treatment-emergent laboratory abnormalities were reported by the investigator as TEAEs.
| participants | Alisertib | Pralatrexate, or Romidepsin, or Gemcitabine |
|---|---|---|
| Neutrophil Count Decreased | 18 | 14 |
| White Blood Cell Count Decreased | 17 | 10 |
| Lymphocyte Count Decreased | 6 | 5 |
| Monocyte Count Decreased | 2 | 1 |
| Lymphocyte Count Increased | 1 | 0 |
| Monocyte Count Increased | 1 | 0 |
| White Blood Cell Count Increased | 1 | 0 |
| Platelet Count Decreased | 15 | 22 |
| Alanine Aminotransferase Increased | 8 | 11 |
| Aspartate Aminotransferase Increased | 5 | 11 |
| Gamma-glutamyltransferase Increased | 6 | 3 |
| Blood Bilirubin Increased | 2 | 1 |
| Hepatic Enzyme Increased | 2 | 0 |
| Liver Function Test Abnormal | 0 | 1 |
| Transaminases Increased | 0 | 1 |
| Blood Alkaline Phosphatase Increased | 9 | 7 |
| Blood Lactate Dehydrogenase Increased | 5 | 1 |
| Blood Creatinine Increased | 3 | 7 |
| Blood Creatinine Decreased | 0 | 1 |
| Blood Urea Increased | 1 | 0 |
| Blood Potassium Decreased | 1 | 4 |
| Blood Magnesium Decreased | 1 | 2 |
| Blood Bicarbonate Decreased | 0 | 1 |
| Blood Calcium Decreased | 0 | 1 |
| Blood Calcium Increased | 1 | 0 |
| Blood Phosphorus Decreased | 0 | 1 |
| Calcium Ionised Increased | 1 | 0 |
| Haemoglobin Decreased | 1 | 3 |
| Haematocrit Increased | 1 | 2 |
| Haematocrit Decreased | 1 | 0 |
| Coagulation Factor XIII Level Decreased | 1 | 0 |
| International Normalised Ratio Increased | 1 | 0 |
| Blood Albumin Decreased | 0 | 2 |
| Myocardial Necrosis Marker Increased | 1 | 0 |
| Troponin Increased | 0 | 1 |
| Blood Glucose Increased | 0 | 1 |
| Immunoglobulins Increased | 1 | 0 |
| Blood Uric Acid Increased | 1 | 0 |
| Enterovirus Test Positive | 0 | 1 |
Vital signs included blood pressure, heart rate and temperature. Individual clinically significant changes in vital signs were reported by the investigator as TEAEs.
| participants | Alisertib | Pralatrexate, or Romidepsin, or Gemcitabine |
|---|---|---|
| Heart Rate Increased | 1 | 0 |
| Body Temperature Increased | 0 | 1 |
| Hypotension | 4 | 6 |
| Orthostatic Hypotension | 2 | 1 |
| Hypertension | 5 | 7 |
| Pyrexia | 48 | 40 |
Complete Response (CR) rate is defined as the percentage of participants with CR as assessed by the IRC using IWG criteria (2007 Cheson). CR= Disappearance of all evidence of disease.
| percentage of participants | Alisertib | Pralatrexate, or Romidepsin, or Gemcitabine |
|---|---|---|
| Complete Response (CR) Rate | 18 (11 to 26) | 27 (18 to 37) |
Time to Progression (TTP) was defined as the time from the date of randomization to the date of first documentation of PD/relapse.
| days | Alisertib | Pralatrexate, or Romidepsin, or Gemcitabine |
|---|---|---|
| Time to Disease Progression (TTP) | 162 (114 to 231) | 116 (101 to 227) |
DOR was defined as the time from the date of first documentation of a PR or better to the date of first documentation of progressive disease (PD)/relapse for responders as assessed by the IRC using IWG criteria. Responders without documentation of PD/relapse were censored at the date of last response assessment that was stable disease (SD) or better.
| days | Alisertib | Pralatrexate, or Romidepsin, or Gemcitabine |
|---|---|---|
| Duration of Response (DOR) | 225 (125 to NA) | 172 (119 to NA) |
Time to Response is defined as the time from the date of randomization to the date of first documentation of PR or better.
| days | Alisertib | Pralatrexate, or Romidepsin, or Gemcitabine |
|---|---|---|
| Time to Response | 62 (57 to 67) | 64 (60 to 71) |
Time to subsequent antineoplastic therapy was defined as the time from randomization to the first date of subsequent antineoplastic therapy (excluding transplant). Participants without subsequent antineoplastic therapy were censored at the date of death or last known to be alive.
| days | Alisertib | Pralatrexate, or Romidepsin, or Gemcitabine |
|---|---|---|
| Time to Subsequent Antineoplastic Therapy | 336 (201 to 490) | 233 (144 to 429) |
No measurements were reported for this outcome.
The FACT-LYM includes the Functional Assessment of Cancer Therapy General Scale (FACT-G) and a 15-item lymphoma-specific subscale (LYM) over the past week. The FACT-G has 27 items that incorporate 4 scales including physical well-being (PWB; 7 items), social/family well-being (SWB, 7 items), emotional well-being (EWB; 6 items), and functional well-being (FWB; 7 items). The combined FACT-LYM instrument consists of a total of a 42 item questionnaire. Each question is answered on a 5- point scale of 0 (not at all) to 4 (very much) for a total possible score of 168. Higher scores indicate better well-being and a positive change from Baseline indicates improvement.
| score on a scale | Alisertib | Pralatrexate, or Romidepsin, or Gemcitabine |
|---|---|---|
| Physical Well-Being, EOT | -2.4 ± 6.21 | -1.3 ± 5.27 |
| Social/Family Well-Being, EOT | -0.3 ± 4.50 | 0.0 ± 4.44 |
| Emotional Well-Being, EOT | -1.4 ± 4.59 | -0.8 ± 3.93 |
| Functional Well-Being, EOT | -2.4 ± 5.40 | -0.3 ± 4.79 |
Collected over First dose to 30 days after last dose of study drug or comparator (Up to 152 Weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Alisertib | 11/137 (8%) | 75/137 (54.7%) | 134/137 (97.8%) |
| Gemcitabine | 5/29 (17.2%) | 18/29 (62.1%) | 29/29 (100%) |
| Pralatrexate | 8/76 (10.5%) | 46/76 (60.5%) | 72/76 (94.7%) |
| Romidepsin | 2/22 (9.1%) | 6/22 (27.3%) | 21/22 (95.5%) |
| Event | Alisertib | Gemcitabine | Pralatrexate | Romidepsin |
|---|---|---|---|---|
| PyrexiaGeneral disorders | 12/137 | 6/29 | 6/76 | 1/22 |
| Febrile neutropeniaBlood and lymphatic system disorders | 24/137 | 1/29 | 1/76 | 0/22 |
| StomatitisGastrointestinal disorders | 7/137 | 0/29 | 11/76 | 0/22 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 2/137 | 2/29 | 3/76 | 2/22 |
| Peripheral T-cell lymphoma unspecifiedNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 2/137 | 2/29 | 1/76 | 2/22 |
| Atrial fibrillationCardiac disorders | 0/137 | 0/29 | 1/76 | 2/22 |
| DehydrationMetabolism and nutrition disorders | 1/137 | 0/29 | 0/76 | 2/22 |
| PneumoniaInfections and infestations | 9/137 | 0/29 | 4/76 | 0/22 |
| ThrombocytopeniaBlood and lymphatic system disorders | 7/137 | 1/29 | 4/76 | 0/22 |
| AnaemiaBlood and lymphatic system disorders | 7/137 | 0/29 | 2/76 | 0/22 |
| Event | Alisertib | Gemcitabine | Pralatrexate | Romidepsin |
|---|---|---|---|---|
| NauseaGastrointestinal disorders | 35/137 | 7/29 | 23/76 | 15/22 |
| StomatitisGastrointestinal disorders | 42/137 | 0/29 | 48/76 | 2/22 |
| AnaemiaBlood and lymphatic system disorders | 74/137 | 7/29 | 30/76 | 6/22 |
| NeutropeniaBlood and lymphatic system disorders | 66/137 | 11/29 | 21/76 | 7/22 |
| DiarrhoeaGastrointestinal disorders | 61/137 | 5/29 | 18/76 | 10/22 |
| ThrombocytopeniaBlood and lymphatic system disorders | 51/137 | 12/29 | 29/76 | 7/22 |
| Decreased appetiteMetabolism and nutrition disorders | 27/137 | 1/29 | 14/76 | 9/22 |
| FatigueGeneral disorders | 49/137 | 11/29 | 14/76 | 6/22 |
| Platelet count decreasedInvestigations | 16/137 | 11/29 | 6/76 | 5/22 |
| AlopeciaSkin and subcutaneous tissue disorders | 43/137 | 0/29 | 1/76 | 0/22 |
Intent-to-treat (ITT) population was defined as all participants who were randomized. The participants were analyzed according to the treatment they were randomized to receive, regardless of any errors of dosing.
| Age, Continuous(years) | Alisertib | Pralatrexate, or Romidepsin, or Gemcitabine | Total |
|---|---|---|---|
| Mean | 61.1 ± 12.69 | 61.4 ± 13.16 | 61.3 ± 12.90 |
| Sex: Female, Male(Participants) | Alisertib | Pralatrexate, or Romidepsin, or Gemcitabine | Total |
|---|---|---|---|
| Female | 46 | 47 | 93 |
| Male | 92 | 86 | 178 |
| Ethnicity (NIH/OMB)(Participants) | Alisertib | Pralatrexate, or Romidepsin, or Gemcitabine | Total |
|---|---|---|---|
| Hispanic or Latino | 25 | 21 | 46 |
| Not Hispanic or Latino | 105 | 107 | 212 |
| Unknown or Not Reported | 8 | 5 | 13 |
| Race/Ethnicity, Customized(participants) | Alisertib | Pralatrexate, or Romidepsin, or Gemcitabine | Total |
|---|---|---|---|
| White | 115 | 114 | 229 |
| Black or African American | 8 | 8 | 16 |
| Asian | 3 | 2 | 5 |
| Other | 7 | 7 | 14 |
| Not Reported | 5 | 2 | 7 |
| Region of Enrollment(participants) | Alisertib | Pralatrexate, or Romidepsin, or Gemcitabine | Total |
|---|---|---|---|
| Australia | 5 | 4 | 9 |
| Austria | 2 | 2 | 4 |
| Belgium | 5 | 3 | 8 |
| Brazil | 12 | 10 | 22 |
| Bulgaria | 0 | 1 | 1 |
| Canada | 3 | 0 | 3 |
| Czech Republic | 5 | 2 | 7 |
| Denmark | 3 | 2 | 5 |
| France | 5 | 3 | 8 |
| Germany | 6 | 1 | 7 |
| Hungary | 9 | 7 | 16 |
| Israel | 0 | 3 | 3 |
| Italy | 6 | 6 | 12 |
| Mexico | 3 | 1 | 4 |
| Netherlands | 0 | 1 | 1 |
| New Zealand | 3 | 2 | 5 |
| Peru | 1 | 3 | 4 |
| Poland | 7 | 3 | 10 |
| Portugal | 1 | 1 | 2 |
| Puerto Rico | 0 | 1 | 1 |
| Romania | 2 | 1 | 3 |
| Russia | 4 | 4 | 8 |
| Spain | 14 | 11 | 25 |
| Sweden | 0 | 3 | 3 |
| Turkey | 10 | 11 | 21 |
| United Kingdom | 3 | 8 | 11 |
| United States | 29 | 39 | 68 |
| Height(cm) | Alisertib | Pralatrexate, or Romidepsin, or Gemcitabine | Total |
|---|---|---|---|
| Mean | 170.3 ± 9.80 | 168.2 ± 8.99 | 169.3 ± 9.45 |
| Weight(kg) | Alisertib | Pralatrexate, or Romidepsin, or Gemcitabine | Total |
|---|---|---|---|
| Mean | 76.85 ± 17.242 | 74.63 ± 19.601 | 75.76 ± 18.437 |
| Body Surface Area (BSA)(m^2) | Alisertib | Pralatrexate, or Romidepsin, or Gemcitabine | Total |
|---|---|---|---|
| Mean | 1.897 ± 0.2465 | 1.855 ± 0.2562 | 1.877 ± 0.2517 |
Showing the first 100 of 152 sites across 31 countries. Choose a country and city above to see the rest.
Ran from Jun 2012 to primary completion in Jun 2015, 36 months.
Results were first posted in Jul 2018, 3 years 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: MLN 8237
Lymphoma, T-Cell, Peripheral →
Millennium Pharmaceuticals, Inc. →